Precigen (PGEN) Construction in Progress (2012 - 2026)
Precigen (PGEN) posted quarterly Construction in Progress of $281000.0 for Q1 2026, down 97.23% year-over-year from $10.1 million in Q1 2025, and up 1.08% quarter-over-quarter from $278000.0 in Q4 2025.
Precigen (PGEN) Construction in Progress (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Construction in Progress for 15 consecutive years, with $281000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Construction in Progress fell 97.23% year-over-year to $281000.0; the TTM figure through Mar 2026 stood at $281000.0 (down 97.23% YoY), while the FY2025 annual figure was $278000.0, down 96.92% from the prior year.
- Construction in Progress rose to $281000.0 in Q1 2026 per PGEN's latest filing, from $278000.0 in the prior quarter.
- Across five years, Construction in Progress topped out at $10.4 million in Q2 2025 and bottomed at $106000.0 in Q2 2023.
- Historically, Construction in Progress has averaged $3.7 million across 5 years, with a median of $1.2 million in 2022.
- Annual changes were most pronounced in 2024 — Construction in Progress surged 7550.0% — and 2026, when it plunged 97.23%.
- Precigen's Construction in Progress stood at $531000.0 in 2022, then jumped by 196.99% to $1.6 million in 2023, then soared by 471.91% to $9.0 million in 2024, then slumped by 96.92% to $278000.0 in 2025, then increased by 1.08% to $281000.0 in 2026.
- Business Quant data shows PGEN's Construction in Progress at $281000.0 in Q1 2026, $278000.0 in Q4 2025, and $263000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 152.67 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 328,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 328,000.00 |
| Mar 31, 2026 | 281,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Sep 30, 2025 | 263,000.00 |
| Jun 30, 2025 | 10.44 Mn |
| Mar 31, 2025 | 10.13 Mn |
| Dec 31, 2024 | 9.02 Mn |
| Sep 30, 2024 | 8.38 Mn |
| Jun 30, 2024 | 8.11 Mn |
| Mar 31, 2024 | 7.31 Mn |
| Dec 31, 2023 | 1.58 Mn |
| Sep 30, 2023 | 892,000.00 |
| Jun 30, 2023 | 106,000.00 |
| Mar 31, 2023 | 151,000.00 |
| Dec 31, 2022 | 531,000.00 |
| Sep 30, 2022 | 1.24 Mn |
| Jun 30, 2022 | 1.06 Mn |
| Mar 31, 2022 | 3.60 Mn |
| Dec 31, 2021 | 1.83 Mn |
| Sep 30, 2021 | 2.73 Mn |